Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4818608 | 0.95 | CYP17A1 (0.46) | CYP17A1CA12CA1CA9PTPN1 | |
| SCHEMBL2347126 | 0.94 | CYP17A1 (0.47) | CYP17A1CA12CA1CA9MAPK14 | |
| SCHEMBL2349306 | 0.85 | PDK1 (0.46) | CYP17A1CA12CA1CA9MAPK14 | |
| SCHEMBL4814686 | 0.81 | MAPK14 (0.69) | MAPK14 | |
| SCHEMBL18165108 | 0.81 | CA12 (0.48) | CYP17A1CA12CA1CA9 | |
| SCHEMBL5544961 | 0.80 | CYP17A1 (0.61) | CYP17A1PTPN1KMT2AMAPTALDH1A1 | |
| SCHEMBL3360413 | 0.79 | CYP17A1 (0.63) | CYP17A1MAPT | |
| SCHEMBL2342676 | 0.79 | PTGS2 (0.51) | CA12CA1CA9MAPK14EGFR | |
| SCHEMBL5098764 | 0.79 | EGFR (0.54) | CA12CA1CA9PTPN1MAPK14 | |
| SCHEMBL4315966 | 0.78 | MEN1 (0.59) | CYP17A1PTPN1KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432289-B2 | 5-Acylamino-1,1′-biphenyl-4-carboxamide derivatives and their use as P38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2008-10-07 | — | — | US | disclosed |
| US-20040242868-A1 | 5-acylamino-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242868-A1 | 5-acylamino-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | MAPK1, MAP3K1, MAPK7 | CYP17A1 2044/4885CA12 4763/4885CA1 3606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.